ECEugene S. Chung

Eugene S. Chung

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eugene S. Chung has a total of 367 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardiotropic AAV gene therapy for heart failure: a phase 1 trial

    by Timothy D. Henry, Eugene S. Chung, Monica Alvisi, Ferzin Sethna, David R. Murray, Jay H. Traverse, Lothar Roessig, Luke Roberts, Swarna Reddy, Youjun Chen, et al.

    Innovative approaches for the treatment of heart failure are needed beyond conventional medical therapy to reverse ventricular dysfunction and modify the course of the disease. AB-1002, a chimeric cardiotropic adeno-associated viral vector that delivers constitutively active protein phosphatase 1 inhibitor 1 to cardiomyocytes, improves cardiac function in preclinical models of heart failure. Here we carried out a phase 1 study to evaluate the safety and feasibility of a single antegrade coronary artery infusion of AB-1002 in patients with nonischemic cardiomyopathy, New York Heart Association class III heart failure, and a left ventricular ejection fraction of 15–35%. Patients received 3.25 × 1013 viral genomes (cohort 1, n = 6) or 1.08 × 1014 viral genomes (cohort 2, n = 5). In total, nine men and two women were included in the study. No adverse events (AEs) or serious AEs were attributed by the investigators to the study treatment; most AEs were mild or moderate in severity. One death occurred, which was considered not to be related to the treatment with AB-1002. Self-limiting, mild, asymptomatic elevations in liver enzymes occurred, predominantly in cohort 2. The preliminary assessments of efficacy outcomes showed improvements in the New York Heart Association class and left ventricular ejection fraction in both cohorts and improvements in peak oxygen consumption and 6-min walk test performance in cohort 1. These results support the further assessment of AB-1002 in clinical trials. The ClinicalTrials.gov registration was NCT04179643.


  • Open Access

    Structural Heart Interventions in Patients with Left Ventricular Assist Devices

    by Puvi Seshiah, Eugene Chung, Santiago Garcia, Joseph Choo, Robert Dowling, Geoffrey Answini, Dean Kereiakes, Gregory Egnaczyk

    Left ventricular assist devices (LVADs) have changed the landscape for patients with advanced heart failure (HF). With advances in pump design and management, patients with LVADs are living longer with improved quality of life despite having more comorbidities and complex structural heart disease. As such, HF cardiologists and surgeons collaborate more frequently with structural heart interventionalists to address the complex problems of patients with LVADs who present at different points of failure in their circuits. Unlike heart transplants and total artificial heart recipients, the native heart and its components must function to maintain successful circulatory support from these assist devices. Multiple points of potential failure of the native heart and the LVAD circuit exist that can result in significant morbidity and mortality. These include regurgitant valve lesions, interatrial shunts, outflow cannula obstruction, and pump thrombosis. Transcatheter interventions can be applied and tailored specifically to the anatomy of the individual in these situations to improve the lives and outcomes of our LVAD patients. This review provides a comprehensive approach for diagnosing and treating structural heart disease associated with patients who have LVADs, focusing on multidisciplinary collaboration and individualized interventional strategies.


  • Rationale and Design of the Personalized Therapy Study: Evaluating Real-World Performance of Two Automated Defibrillation Therapy Algorithms

    by Raymond Yee, Charles J. Love, Daniel W. Kaiser, Ulrika Birgersdotter-Green, Yong-Mei Cha, Jagmeet P. Singh, Shufeng Liu, Yan Zhang, Eugene S. Chung


  • Top Cited Papers
    Open Access

    Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial

    by Gregg W. Stone, JoAnn Lindenfeld, Josep Rodés-Cabau, Stefan D. Anker, Michael R. Zile, Saibal Kar, Richard Holcomb, Michael P. Pfeiffer, Antoni Bayes-Genis, Jeroen J. Bax, et al.

    BACKGROUND: An interatrial shunt may provide an autoregulatory mechanism to decrease left atrial pressure and improve heart failure (HF) symptoms and prognosis. METHODS: Patients with symptomatic HF with any left ventricular ejection fraction (LVEF) were randomized 1:1 to transcatheter shunt implantation versus a placebo procedure, stratified by reduced (≤40%) versus preserved (>40%) LVEF. The primary safety outcome was a composite of device-related or procedure-related major adverse cardiovascular or neurological events at 30 days compared with a prespecified performance goal of 11%. The primary effectiveness outcome was the hierarchical composite ranking of all-cause death, cardiac transplantation or left ventricular assist device implantation, HF hospitalization, outpatient worsening HF events, and change in quality of life from baseline measured by the Kansas City Cardiomyopathy Questionnaire overall summary score through maximum 2-year follow-up, assessed when the last enrolled patient reached 1-year follow-up, expressed as the win ratio. Prespecified hypothesis-generating analyses were performed in patients with reduced and preserved LVEF. RESULTS: Between October 24, 2018, and October 19, 2022, 508 patients were randomized at 94 sites in 11 countries to interatrial shunt treatment (n=250) or a placebo procedure (n=258). Median (25th and 75th percentiles) age was 73.0 years (66.0, 79.0), and 189 patients (37.2%) were women. Median LVEF was reduced (≤40%) in 206 patients (40.6%) and preserved (>40%) in 302 patients (59.4%). No primary safety events occurred after shunt implantation (upper 97.5% confidence limit, 1.5%; P P =0.20). However, patients with reduced LVEF had fewer adverse cardiovascular events with shunt treatment versus placebo (annualized rate 49.0% versus 88.6%; relative risk, 0.55 [95% CI, 0.42–0.73]; P P =0.0001; P interaction <0.0001). There were no between-group differences in change in Kansas City Cardiomyopathy Questionnaire overall summary score during follow-up in all patients or in those with reduced or preserved LVEF. CONCLUSIONS: Transcatheter interatrial shunt implantation was safe but did not improve outcomes in patients with HF. However, the results from a prespecified exploratory analysis in stratified randomized groups suggest that shunt implantation is beneficial in patients with reduced LVEF and harmful in patients with preserved LVEF. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03499236.


  • Open Access

    Racial Disparities in Clinical Outcomes of Takotsubo Cardiomyopathy: An Analysis of the National Inpatient Sample 2006 to 2018

    by Chi N. Duong, Quoc V. P. Bui, Thomas Duong, Dai Q. Phan, Jan Mazur, Eugene Chung, Vien T. Truong

    Background: This study aimed to evaluate the impact of race on in‐hospital outcomes of Takotsubo cardiomyopathy using the National Inpatient Sample. Methods and Results: We conducted a retrospective study using data from the National Inpatient Sample database 2006 to 2018. We focused on Takotsubo cardiomyopathy hospitalizations, excluding those with acute coronary syndrome as the primary diagnosis. Two study groups consisted of White patients or Black patients. Univariate and multivariable logistic models evaluated race's effect on death, cardiac arrest, cardiogenic shock, length of stay, while adjusting for potential confounders. The Bayesian model averaging technique was used to further elucidate the factors influencing death within each racial group. Significant differences were observed between the 2 racial groups. Black patients presented at a younger age, had a higher proportion of men, a higher burden of comorbidities, and a lower median household income compared with their White counterparts. In the univariate model, the Black cohort showed an increased risk of cardiac arrest (odds ratio, 1.45 [95% CI, 1.15–1.82]). However, the difference did not reach statistical significance in the multivariable model. Black patients also had a significantly longer hospital stay in both the univariate model (risk ratio, 1.26 [95% CI, 1.22–1.31]) and the multivariable model (risk ratio, 1.06 [95% CI, 1.04–1.07]). No significant difference in all‐cause death was observed between the racial groups. Conclusions: The outcome differences between 2 racial groups in our study are likely influenced by racial disparities in demographics, comorbidities, and socioeconomic factors. Individualized care based on racial group needs is crucial in clinical practice.


  • Abstract 18204: Application of Machine Learning in Predicting All-Cause Mortality in Patients With Left Ventricular Assist Device

    by Vien T Truong, Binh Nguyen, Alex Xing X Wang, Phan Dai, Vivek Patel, Mansoor Ahmad, Muhammad Saad Siddique, Syed Muhammad Usama, Avilash Mondal, Kevin Quach, et al.

  • A Review of Heart Failure in Patients with COVID-19

    by Hanad Bashir, Mehmet Yildiz, John Cafardi, Ankit Bhatia, Santiago Garcia, Timothy D. Henry, Eugene S. Chung


  • IMPACT OF MITRAL VALVE INTERVENTION ON CLINICAL OUTCOMES FOLLOWING LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION: AN INTERMACS ANALYSIS

    by Vien T. Truong, Sonela Skenderi, Krunalkumar Patel, Abhishek Dutta, Aaron Douen, Durgesh Agrawal, Avilash Mondal, Mansoor Ahmad, Muhammad Saad Siddique, Ahmad Al Homaid, et al.

  • Open Access

    Moderate Aortic Stenosis in Patients With Heart Failure

    by Vien T. Truong, John Ernst, Akhil Pallerla, Amitesh Verma, Cheryl Bartone, Cassady Palmer, Eugene S. Chung

    Korean Circulation Journal 대한심장학회지 순환기 Truong VT, et al. Korean Circ J. 2022 Oct;52:e100. https://doi.org/10.4070/kcj.2022.0131


  • Left Ventricular Assist Device in Patients With Alcohol Abuse or Illicit Drug Use

    by Vien T. Truong, Gregory F. Egnaczyk, Thomas M. O'BRien, Timothy E. Raymond, Stephanie Gilardi, Satya S. Shreenivas, Answini A. Geoffrey, Eugene S. Chung